Immunotherapies

To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
Vaccine Adjuvant: Flagellin-Based Adjuvant for Tumor Cell Vaccines 04A028
Antibodies: MARCO for Enhanced Dendritic Cell Vaccine Efficacy 07MB004
Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination 11MA013
TAG72-CD3: Bispecific Antibody for Targeted Cancer Immunotherapy 14MB072
 Vaccine: Use of a Variant Survivin Vaccine to Treat Myeloma 14MB098
TLR9: CARs (chimeric antigen receptors) that Recognize TLR9 16MA025
DOR: Delta opioid receptor ligand and anti-PD1 checkpoint inhibitor conjugates for immunotherapy of lung cancer 16MA029N
AaPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain for Producing CAR-Ts 16MB049
AaPC: Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy 16MB050
TAG72: CAR-T cell constructs (chimeric antigen receptors) that Recognize TAG72 16MB057
IL-13Rα2: CAR-T cell constructs (chimeric antigen receptors) that Recognize IL-13Rα2 16MB069
CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy 17MA007
TILs: Rapid method for culture of TILs from core needle biopsies of solid tumors 17MA012
CLEC12A: CAR-T cell constructs (chimeric antigen receptors) that Recognize CLEC12A to Treat AML 17MA041
CD99: CAR-T cell constructs (chimeric antigen receptors) that Recognize CD99 to Treat AML 17MA042
MIC & RAET1/ULBP: CAR-T cell constructs that use the NKG2D protein to bind MIC and RAET1/ULBP proteins to treatl AML 18MA023N